For in vitro diagnostic use. Others Elecsys Total-Tau CSF IVD Elecsys® Total-Tau CSF CPS_000534 08 846 685 190 8 846 685 190 08846685190 8846685190 08846685190 tTau Elecsys E2G 100 V2 Elecsys Total-Tau CSF 07613336167649 Reagents, kits 100 tests cobas e 402/801 true 08 846 634 160 8 846 634 160 08846634160 8846634160 08846634160 tTau Elecsys cobas e60 V2 Elecsys Total-Tau CSF 07613336221761 Reagents, kits 60 tests cobas e 411/601/602 true 08846685501 Elecsys Total-Tau CSF en 2 FF000000065F9B0E FF0000000648BA0E 08846685190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useElecsys β‑Amyloid (1‑42) CSF II and Elecsys Total‑Tau CSF are in vitro electrochemiluminescence immunoassays for the measurement of the β‑Amyloid (1‑42) (Abeta42) and Total‑Tau (tTau) protein concentration in cerebrospinal fluid (CSF) from adult patients aged 55 years and older being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment to generate a tTau/Abeta42 ratio value. A negative result, defined as tTau/Abeta42 ratio value below cutoff or an Abeta42 value above the measuring range, is consistent with a negative amyloid positron emission tomography (PET) scan result. A negative result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive result, defined as tTau/Abeta42 ratio value above cutoff, is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder. The tTau/Abeta42 ratio result is used as an adjunct to other clinical diagnostic evaluations. Limitations of useThe performance of the tTau/Abeta42 ratio has not been established for:Predicting development of dementia or other neurologic conditionsMonitoring responses to therapies en 08846634501 Elecsys Total-Tau CSF en 2 FF0000000656A60E FF000000064F2B0E 08846634160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useElecsys β‑Amyloid (1‑42) CSF II and Elecsys Total‑Tau CSF are in vitro electrochemiluminescence immunoassays for the measurement of the β‑Amyloid (1‑42) (Abeta42) and Total‑Tau (tTau) protein concentration in cerebrospinal fluid (CSF) from adult patients aged 55 years and older being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment to generate a tTau/Abeta42 ratio value. A negative result, defined as tTau/Abeta42 ratio value below cutoff or an Abeta42 value above the measuring range, is consistent with a negative amyloid positron emission tomography (PET) scan result. A negative result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive result, defined as tTau/Abeta42 ratio value above cutoff, is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder. The tTau/Abeta42 ratio result is used as an adjunct to other clinical diagnostic evaluations. Limitations of useThe performance of the tTau/Abeta42 ratio has not been established for:Predicting development of dementia or other neurologic conditionsMonitoring responses to therapies en

User Profile

Select your user profile

Elecsys^® Total-Tau CSF

Don't wait to confirm amyloid positivity and unlock new therapies for more patients.